Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Address: Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; American Society of Hypertension Comprehensive Hypertension Center, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.; National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.; Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.; Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.; Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.; Okayama University, Okayama, Japan.; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health Science, Aarhus University, Aarhus, Denmark.; George Institute for Global Health and University of New South Wales, Sydney, New South Wales, Australia.; Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto and the Northern Ontario School of Medicine, Toronto, Ontario, Canada.; Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; George Institute for Global Health and University of New South Wales, Sydney, New South Wales, Australia.